


## Tubulin polymerization-IN-9

<b>Cat. No.:</b>	HY-146718
<b>CAS No.:</b>	2485020-93-5
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>19</sub> NO <sub>5</sub> Se
<b>Molecular Weight:</b>	420.32
<b>Target:</b>	Microtubule/Tubulin; Apoptosis
<b>Pathway:</b>	Cell Cycle/DNA Damage; Cytoskeleton; Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Tubulin polymerization-IN-9 is a potent tubulin inhibitor with IC <sub>50</sub> of 1.82 μM. Tubulin polymerization-IN-9 causes cell cycle arrest at G2/M phase, and induces cell apoptosis and depolarized mitochondria of K562 cells. Tubulin polymerization-IN-9 has potent anti-vascular and antitumor activities <sup>[1]</sup> .												
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 1.82 μM (tubulin) <sup>[1]</sup>												
<b>In Vitro</b>	<p>Tubulin polymerization-IN-9 (compound 11k) (0.1, 1, 10 μM; 72 hours) has potent activity against these three cancer cell lines with IC<sub>50</sub> values ranging from 0.287 to 0.621 μM<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-9 (0.15, 0.3 and 0.6 μM; 24 hours) induces a dose-dependent collapse of the microtubule networks<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-9 (0.15, 0.3 and 0.6 μM; 48 hours) observes a gradual accumulation of cells at G2/M phase in K562 cells<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-9 (0.15, 0.3 and 0.6 μM; 72 hours) effectively induces cell apoptosis in K562 cells in a concentration-dependent manner<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-9 (0.15, 0.3 and 0.6 μM; 24 hours) causes mitochondrial depolarization of K562 cells in the process of apoptosis<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p><b>Cell Proliferation Assay</b></p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 HepG2 and HCT-8 cells<sup>[1]</sup></td> </tr> <tr> <td>Concentration:</td> <td>0.1, 1, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Showed potent activity against these three cancer cell lines with IC<sub>50</sub> values ranging from 0.287 to 0.621 μM.</td> </tr> </table> <p><b>Immunofluorescence</b></p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 cells<sup>[1]</sup></td> </tr> <tr> <td>Concentration:</td> <td>0.15, 0.3 and 0.6 μM</td> </tr> </table>	Cell Line:	K562 HepG2 and HCT-8 cells <sup>[1]</sup>	Concentration:	0.1, 1, 10 μM	Incubation Time:	72 hours	Result:	Showed potent activity against these three cancer cell lines with IC <sub>50</sub> values ranging from 0.287 to 0.621 μM.	Cell Line:	K562 cells <sup>[1]</sup>	Concentration:	0.15, 0.3 and 0.6 μM
Cell Line:	K562 HepG2 and HCT-8 cells <sup>[1]</sup>												
Concentration:	0.1, 1, 10 μM												
Incubation Time:	72 hours												
Result:	Showed potent activity against these three cancer cell lines with IC <sub>50</sub> values ranging from 0.287 to 0.621 μM.												
Cell Line:	K562 cells <sup>[1]</sup>												
Concentration:	0.15, 0.3 and 0.6 μM												

Incubation Time:	24 hours
Result:	Induced a dose-dependent collapse of the microtubule networks.
Cell Cycle Analysis	
Cell Line:	K562 cells <sup>[1]</sup>
Concentration:	0.15, 0.3 and 0.6 $\mu$ M
Incubation Time:	48 hours
Result:	Observed a gradual accumulation of cells at G2/M phase in K562 cells.
Apoptosis Analysis	
Cell Line:	K562 cells <sup>[1]</sup>
Concentration:	0.15, 0.3 and 0.6 $\mu$ M
Incubation Time:	72 hours
Result:	Effectively induced cell apoptosis in K562 cells in a concentration-dependent manner.

#### In Vivo

Tubulin polymerization-IN-9 (15 and 30 mg/kg; IV; once a day, for 21 days) effectively suppresses the tumor volume and reduces tumor weight by 71.1% at a dose of 30 mg/kg<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ICR mice (5 weeks; injected with H22 cells; n=6) <sup>[1]</sup>
Dosage:	15 and 30 mg/kg
Administration:	IV; once a day, for 21 days
Result:	Effectively suppressed the tumor volume and reduced tumor weight by 71.1% at a dose of 30 mg/kg.

## REFERENCES

[1]. Zhu H, Sun H, Liu Y, et al. Design, synthesis and biological evaluation of vinyl selenone derivatives as novel microtubule polymerization inhibitors. Eur J Med Chem. 2020;207:112716.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA